Characterization of macrophage activation states in patients with cystic fibrosis

Journal of Cystic Fibrosis

Volumn 9, Issue 5, 2010, Pages 314-322

  Murphy, Brian S ^a   Bush, Heather M ^b   Sundareshan, Vidya ^a   Davis, Christina ^a   Hagadone, Jennifer ^a   Cory, Theodore J ^a   Hoy, Heather ^a   Hayes, Don ^a   Anstead, Michael I ^a   Feola, David J ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b Peter P Bosomworth Professor of Health Services Research and Policy   (United States)

Author keywords

Azithromycin; Cystic fibrosis; Immunomodulation; Inflammation; Macrophage; Pseudomonas; Pulmonary

Indexed keywords

ARGINASE; AZITHROMYCIN; CD11B ANTIGEN; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MANNOSE RECEPTOR; STEROID; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ACHROMOBACTER XYLOSOXIDANS; ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; BORDETELLA BRONCHISEPTICA INFECTION; CHILD; CLINICAL ARTICLE; CYSTIC FIBROSIS; ENZYME ACTIVITY; FEMALE; FORCED EXPIRATORY VOLUME; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE; HUMAN; KLEBSIELLA INFECTION; KLEBSIELLA OXYTOCA; LUNG ALVEOLUS MACROPHAGE; LUNG FUNCTION; LUNG LAVAGE; MACROPHAGE ACTIVATION; MALE; PRESCHOOL CHILD; PROTEIN EXPRESSION; PSEUDOMONAS INFECTION; SCHOOL CHILD; SERRATIA INFECTION; SERRATIA MARCESCENS; SPUTUM ANALYSIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STENOTROPHOMONAS MALTOPHILIA; UPREGULATION;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; ARGINASE; AZITHROMYCIN; BIOLOGICAL MARKERS; CELL COUNT; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; CYTOKINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INFANT; LECTINS, C-TYPE; MACROPHAGE ACTIVATION; MACROPHAGES; MALE; MANNOSE-BINDING LECTINS; MIDDLE AGED; PHENOTYPE; PSEUDOMONAS INFECTIONS; RECEPTORS, CELL SURFACE; STEROIDS; UP-REGULATION; YOUNG ADULT;

EID: 77956898288     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2010.04.006     Document Type: Article

References (38)

1. Kosorok M.R., Jalaluddin M., Farrell P.M., Shen G., Colby C., Laxova A., et al. Comprehensive analysis of risk factors for acquisition of Pseudomonas aeruginosa in young children with cystic fibrosis. Ped Pulmonol 1998, 26(2):81-88.
2. Li Z., Kosorok M.R., Farrell P.B., Laxova A., West S., Green C., et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005, 293(5):581-588.
3. Murphy T.F., Brauer A.L., Eschberger K., Lobbins P., Grove L., Cai X., et al. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008, 177:853-860.
4. May T., Shinabarger D., Maharaj R., Kato J., Chu L., DeVault J., et al. Alginate synthesis by Pseudomonas aeruginosa: a key pathogenic factor in chronic pulmonary infections of cystic fibrosis patients. Clin Microbiol Rev 1991, 4:191-206.
5. Hartl D., Griese M., Kappler M., Zissel G., Reinhardt D., Rebhan C., et al. Pulmonary TH2 response in Pseudomonas aeruginosa - infected patients with cystic fibrosis. J Allergy Clin Immunol 2006, 117(1):204-211.
6. Moser C., Kjaergaard S., Pressler T. The immune response to chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients is predominantly of the Th2 type. APMIS 2000, 108:329-335.
7. Stout R.D., Suttles J. Functional plasticity of macrophages: reversible adaptation to changing microenvironments. J Leukoc Biol 2004, 76(3):509-513.
8. Montaner L.J., da Silva R.P., Sun J., Sutterwala S., Hollinshead M., Vaux D., et al. Type 1 and type 2 cytokine regulation of macrophage endocytosis: differential activation by IL-4/IL-13 as opposed to IFN-gamma or IL-10. J Immunol 1999, 162(8):4606-4613.
9. Stein M., Keshav S., Harris N., Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med 1992, 176(1):287-292.
10. Kristiansen M., Graversen J.H., Jacobsen C., Sonne O., Hoffman H.J., Law S.K., et al. Identification of the haemoglobin scavenger receptor. Nature 2001, 409(6817):198-201.
11. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends in immunology 2002, 23(11):549-555.
12. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003, (3):23-25.
13. Prasse A., Pechkovsky D.V., Toews G.B., Jungraithmayr W., Kollert F., Goldmann T., et al. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med 2006, 173(7):781-792.
14. Hesse M., Modolell M., La Flamme A.C., Schito M., Fuentes J.M., Cheever A.W., et al. Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of l-arginine metabolism. J Immunol 2001, 167(11):6533-6544.
15. Knudson R., Lebowitz M., CJ H., Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983, 127(6):725-734.
16. Bagchi A., Viscardi R.M., Taciak V., Ensor J.E., McCrea K.A., Hasday J.D. Increased activity of interleukin-6 but not tumor necrosis factor-α in lung lavage of premature infants is associated with the development of bronchopulmonary dysplasia. Pediatr Res 1994, 36:244-252.
17. Corraliza I.M., Campo M.L., Soler G., Modolell M. Determination of arginase activity in macrophages: a micromethod. Journal of immunological methods 1994, 174(1-2):231-235.
18. Chen R., Lowe L., Wilson J.D., Crowther E., Tzeggai K., Bishop J.E., et al. Simultaneous quantification of six human cytokines in a single sample using microparticle-based flow cytometric technology. Clin Chem 1999, 45(9):1693-1694.
19. Grasemann H., Schwiertz R., Matthiesen S., Racké K., Ratjen F. Increased arginase activity in cystic fibrosis airways. Am J Respir Crit Care Med 2005, 172:1523-1528.
20. Murphy B.S., Sundareshan V., Cory T.J., Hayes D., Anstead M.I., Feola D.J. Azithromycin alters macrophage phenotype. J Antimicrob Chemother 2008, 61(3):554-560.
21. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003, 3(1):23-35.
22. Goerdt S., Orfanos C.E. Other functions, other genes: alternative activation of antigen-presenting cells. Immunity 1999, 10:137-142.
23. Munder M., Eichmann K., Modolell M. Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype. J Immunol 1998, 160(11):5347-5354.
24. Lakos G., Melichian D., Wu M., Varga J. Increased bleomycin-induced skin fibrosis in mice lacking the Th1-specific transcription factor T-bet. Pathobiology 2006, 73(5):224-237.
25. Baylin S., Rosenstein B., Marton L., Lockwood D. Age-related abnormalities of ciruclating polyamines and diamine oxidase activity in cystic fibrosis heterozygotes and homozygotes. Pediatric Research 1980, 14:921-925.
26. Fong C.H., Bebien M., Didierlaurent A., Nebauer R., Hussell T., Broide D., et al. An antiinflammatory role for IKKbeta through the inhibition of "classical" macrophage activation. J Exp Med 2008, 205(6):1269-1276.
27. Mulet X., Macia M.D., Mena A., Juan C., Perez J.L., Oliver A. Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of NFκB mutants. Antimicrob Agents Chemother 2009, 53(4):1552-1560.
28. Vignola A.M., Rennar S.I., Hargreave F.E., Fah J.V., Bonsignore M.R., Djukanovic R., et al. Standardised methodology of sputum induction and processing: future directions. Eur Respir J Suppl 2002, 37:51s-55s.
29. Brombacher F. The role of interleukin-13 in infectious diseases and allergy. BioEssays 2000, 22(7):646-656.
30. Maarsingh H., Pera T., Meurs H. Arginase and pulmonary diseases. Naunyn-Schmiedeberg's Arch Pharmacol 2008, 378(2):171-184.
31. Moser C., Hougen H.P., Song Z., Rygaard J., Kharazmi A., Hoiby N. Early immune response in susceptible and resistant mice strains with chronic Pseudomonas aeruginosa lung infection determines the type of T-helper cell response. APMIS 1999, 107:1093-1100.
32. Di A., Brown M.E., Deriy L.V., Li Cy., Szeto F.l., Chen Y.M., Huang P., Tong J.K., Naren A.P., Bindokas V., Palfrey H.C., Nelson D.J. CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. Nat Cell Biol 2006, 8:933-952.
33. Haggie P.M., Verkman A.S. CFTR-independent phagosomal acidification in macrophages. J Biol Chem 2007, 282:31422-31428.
34. Vij N., Mazur S., Zeitlin P.L. CFTR is a negative regulator of NFκB mediated innate immune response. PLoS One 2009, 4(2):e4664.
35. Aghai Z.H., Kode A., Saslow J.G., Nakhla T., Farhath S., Stahl G.E., Eydelman R., Strande L., Leone P., Rahman I. Azithromycin suppresses activation of nuclear factor-kappa B and synthesis of pro-inflammatory cytokines in tracheal aspirate cells from premature infants. Pediatr Res 2007, 62:483-488.
36. Cigana C., Assael B.M., Melotti P. Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. Antimicrob Agents Chemother 2007, 51:975-981.
37. Reinhardt N., Chen C.I.U., Loppow D., Schnik T., Kleinau I., Jorres R.A., Wahn U., Magnussen H., Paul K.P. Cellular profiles of induced sputum in children with stable cystic fibrosis: comparison with BAL. Eur Respir J 2003, 22:497-502.
38. Jung A., Kleinau I., Schonian G., Bauernfeind A., Chen C., Griese M., Doring G., Gobel U., Wahn U., Paul K.P. Sequential genotyping of Pseudomonas aeruginosa from upper and lower airways of cystic fibrosis patients. Eur Respir J. 2002, 20:1457-1463.